Optimi Health and Psyence Biomedical Sign LOI for Psilocybin Supply Agreement

LOS ANGELES- Optimi Health, a GMP-approved and Health Canada-licensed psychedelics pharmaceutical manufacturer, has entered into a non-binding Letter of Intent (LOI) with Psyence Biomedical Ltd. . This partnership positions Optimi as the exclusive supplier of nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization efforts, particularly within the FDA-approved palliative care context.

Under the terms of the LOI, Optimi will provide Chemistry, Manufacturing, and Control (CMC) support for Psyence’s regulatory submissions and any future Investigational New Drug (IND) applications. Psyence will secure exclusive rights to Optimi’s drug candidate for treatment use in palliative care.

Optimi CEO Bill Ciprick highlighted the partnership’s potential to advance psilocybin-based therapies, while Psyence CEO Dr. Neil Maresky emphasized the strategic importance of the agreement in supporting Psyence’s clinical trials and regulatory submissions.

This LOI is non-binding, and there is no guarantee that a fully binding agreement will be executed.